The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.
 
Naureen Starling
Honoraria - Amgen; AstraZeneca; BMS; BMS; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Janssen; MSD; MSD Oncology; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer; Seagen; SERVIER
Research Funding - AstraZeneca (Inst); BMS (Inst); Guardant Health (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Guardant Health; MSD Oncology; SERVIER
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Katerina Neumann
No Relationships to Disclose
 
Bruce Colwell
Honoraria - Eisai; Merck; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Merck; Pfizer; Roche; Taiho Oncology
 
John H Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Inivata; Janssen Oncology; Lilly; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Silverback Therapeutics; Taiho Oncology; Takeda; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene; Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Lilly (Inst); Nektar (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Al Bowen Benson III
Consulting or Advisory Role - Abbvie; Amgen Astellas BioPharma; Apexigen; Array BioPharma; Artemida Pharma; Boehringer Ingelheim; Boston Scientific; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; GlaxoSmithKline; HalioDx; Hutchmed; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Natera; Novartis/Pfizer; Pfizer; Pfizer; Samsung Bioepis; Therabionic; Xencor
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITM Solucin (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)
 
Jamil Asselah
Employment - To Follow
 
Yoshito Komatsu
No Relationships to Disclose
 
Sara Marques
Travel, Accommodations, Expenses - Alvotech
 
Ken Edwards
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Sean Barton O'Donnell
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Neda Stjepanovic
Employment - Debiopharm Group (I); GlaxoSmithKline
 
Jenny F. Seligmann
Honoraria - Merck Serono; Pierre Fabre; SERVIER
Consulting or Advisory Role - Elevation Oncology; Pierre Fabre; Zentalis
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex